Aspire Biopharma Holdings Inc.

04/08/2026 | Press release | Distributed by Public on 04/08/2026 15:27

Amendment to Annual Report (Form 10-K/A)

This Amendment No. I on Form 10-K/A (this "Amendment") amends the Annual Report on Form 10-K of Aspire Biopharma Holdings, Inc. (the "Company") for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 30, 2026 (the "Original Filing"). This Amendment is being filed:

● To file the Report of Independent Registered Public Accounting Firm of our predecessor auditor, Bush & Associates CPA LLC (the "Auditor Report") related to the Company's financial statements as of and for the year ended December 31, 2024, which was inadvertently omitted in the Original Filing.

This Amendment is being filed solely to file the Auditor Report. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the date of the Original Filing or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant's other filings with the Securities and Exchange Commission.

This Amendment includes new certifications by the Company's principal executive officer and principal financial officer as Exhibits 31.1, 31.2, 32.1 and 32.2, and the Auditor Consent as Exhibit 23.1.

Aspire Biopharma Holdings Inc. published this content on April 08, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 08, 2026 at 21:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]